Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | GYS1 | P13807 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17323618 | 0.83 | ALDH1A1 (0.48) | ALDH1A1GYS1 | |
| SCHEMBL4894873 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CHRNA4TSHRKMT2AHPGD | |
| SCHEMBL4894867 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CHRNA4TSHRKMT2AHPGD | |
| SCHEMBL15126220 | 0.78 | VHL (0.53) | ALDH1A1KMT2AHPGD | |
| SCHEMBL3340458 | 0.77 | CHRNA4 (0.49) | HCAR2CHRNA4MEN1KMT2A | |
| SCHEMBL15904336 | 0.77 | USP30 (0.48) | ALDH1A1TSHRCA2L3MBTL1GYS1 | |
| SCHEMBL3340302 | 0.76 | CHRNA4 (0.60) | HCAR2CHRNA4MEN1KMT2A | |
| SCHEMBL21696945 | 0.76 | ACE (0.46) | ALDH1A1KMT2AHPGD | |
| SCHEMBL3335412 | 0.76 | CHRNA4 (0.45) | HCAR2CHRNA4MEN1KMT2A | |
| SCHEMBL6786504 | 0.75 | GYS1 (0.59) | ALDH1A1KMT2ACA2L3MBTL1GYS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ALDH1A1 289/4885HCAR2 4422/4885CHRNA4 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.